Incyte Unveils 54‑Week Stop‑HS Data for Povorcitinib at AAD 2026
Incyte shares 54‑week Phase‑3 STOP‑HS data on povorcitinib, revealing longer‑term efficacy and safety for hidradenitis suppurativa at AAD 2026.
2 minutes to read
Incyte Corp
Incyte Secures $35M Option for Precision JAK2 Inhibitor, Boosting MPN Pipeline and Share Price
Incyte’s $35 million option for Prelude’s mutant‑selective JAK2V617F inhibitor could accelerate its MPN pipeline, boost precision oncology, and lift shares to a new 52‑week high.
3 minutes to read
Incyte’s Povorcitinib Achieves Milestone in HS Treatment, Boosting Strategic Momentum
Incyte Corporation’s povorcitinib, a small-molecule JAK1/2 inhibitor, has shown promising 24-week efficacy data in treating hidradenitis suppurativa, potentially positioning the company for significant growth and a regulatory submission in the US la…
3 minutes to read
Incyte Corp Surpasses Q2 Earnings Expectations with Strong Jakafi Performance Amid Market Volatility
Incyte Corp’s Q2 earnings exceeded expectations, with a net income of $405 million and a 16% revenue increase, driven by strong demand for its key product Jakafi.
2 minutes to read
Incyte Corporation Welcomes New CEO Bill Meury, Stock Soars Amid M&A Optimism
Incyte Corporation has appointed Bill Meury as its new CEO, sparking a 4.18% rise in stock price and investor optimism for new strategic directions.
2 minutes to read
Incyte Corp Reports Strong Q1 Performance, Raises Revenue Guidance for Jakafi
Incyte Corp reports strong Q1 2025 performance, exceeding revenue estimates and raising revenue guidance for its flagship product Jakafi to $3 billion.
2 minutes to read
Incyte Corp to Showcase Oncology Data at AACR and ASCO 2025 Conferences
Incyte Corporation will present new oncology data at the AACR and ASCO Annual Meetings in 2025, highlighting its commitment to advancing cancer treatment and research.
2 minutes to read